Drugs / REGEND001
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06987214 | May 2025 → May 2029 expected | bronchiectasis | Ruijin Hospital | Recruiting | No outcome recorded |
| Phase 1 | NCT05657184 | Jul 2021 → Jun 2023 | idiopathic pulmonary fibrosis | Regend Therapeutics | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06081621 | Dec 2023 → Mar 2025 | idiopathic pulmonary fibrosis | Regend Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT05638776 | Dec 2022 → Jul 2025 | chronic obstructive pulmonary disease | Regend Therapeutics | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | REGEND001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06987214 ↗ |
| Action | Restore | “ability to regenerate lung tissue” NCT05638776 ↗ |
| Modality | Cell therapy | “REGEND001 cell therapy, comprised of airway basal cells with ability to regenerate lung tissue” NCT05638776 ↗ |
| Route | Other | “administrated by bronchoscopy” NCT06081621 ↗ |